Joseph Edelman
CEO & Founder @ Perceptive Advisors
New York, United States
Joseph Edelman is a post-ipo equity investor at Perceptive Advisors in New York focused on Biotechnology and Pharmaceutical. Joseph Edelman is based out of New York, New York, and is the CEO & founder of Perceptive Advisors. Joseph previously worked at Aries Fund as a senior analyst. Joseph Edelman attended New York University.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries Joseph Edelman invests in
Stages Joseph Edelman invests in
Countries Joseph Edelman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (42%)
- Pharmaceutical 5 (42%)
- Medical 4 (33%)
- Health Care 2 (17%)
- Therapeutics 2 (17%)
Stage
- Post-IPO Equity 5 (42%)
- Series B 2 (17%)
- Series C 2 (17%)
- Post-IPO Debt 1 (8%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders.Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reachand positively impact everyone. | $90M / Post-IPO Equity / Dec 18, 2025 | ||
| Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost toachieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products. | $350M / Post-IPO Equity / Feb 28, 2024 | ||
| Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts. | $42.3M / Post-IPO Equity / Jul 17, 2020 | ||
| Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders.Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reachand positively impact everyone. | $85M / Series B / Jun 04, 2020 | ||
| Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts. | $62M / Series C / Jul 23, 2019 | ||
| Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases. Its mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S.,China, Hong Kong, Taiwan, and the U.K. | $100M / Post-IPO Equity / May 06, 2019 | ||
| Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases. Its mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S.,China, Hong Kong, Taiwan, and the U.K. | $50M / Post-IPO Equity / Jul 02, 2018 | ||
| Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases. Its mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S.,China, Hong Kong, Taiwan, and the U.K. | $50M / Post-IPO Debt / Jul 02, 2018 | ||
| Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost toachieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products. | $63.5M / Series B / Mar 13, 2018 | ||
| Vensun Pharmaceuticals is a pharmaceutical company developing generic prescription products in various dosage forms. As a rapidly emerging generic pharmaceutical company, Vensun has filed several Abbreviated New Drug Applications (ANDAs) with the FDA through its partnerships and currently has over 30 products in active development. We are activelyseeking additional opportunities for partnerships, strategic alliances, and product acquisitions to enhance our existing development portfolio. | $22.5M / Series C / Dec 01, 2016 | ||
| See all 12 investments → | |||
Co-Investors
About Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.
Perceptive Advisors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ellen Hukkelhoven
Head of Investment Research
|
|||
Fred Callori
Managing Director of Venture
|
|||
|
Joseph Edelman
CEO & Founder
|
|||
Orly Mishan
Managing Director, Perceptive Discovery
|
|||
Adam Stone
Chief Investment Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Joseph Edelman invest in?
Joseph Edelman invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joseph Edelman?
Public channels for Joseph Edelman include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joseph Edelman last invest?
The most recent investment recorded for Joseph Edelman closed in Dec 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
